on ABIVAX (EPA:ABVX)
Abivax Appoints Mark Stenhouse as Observer and Strategic Advisor
On November 13, 2024, Abivax announced the appointment of Mark Stenhouse as a Board Observer and Advisor. Former COO of Prometheus, recently acquired by Merck for $10.8 billion, Stenhouse has over 30 years of experience in the biopharmaceutical industry. Prior to Prometheus, he was Vice President, Immunology at AbbVie, overseeing HUMIRA® in the United States.
Marc de Garidel, CEO of Abivax, expressed his satisfaction with this appointment, highlighting Stenhouse's expertise as an asset for the progression of Abivax's projects, including the development of Obefazimod. Stenhouse is enthusiastic and welcomes Obefazimod's potential to address unmet therapeutic needs in the medical community.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news